Double-blinded randomized controlled trial to reveal the effects of Brazilian propolis intake on rheumatoid arthritis disease activity index; BeeDAI.

<h4>Background and aims</h4>Brazilian propolis reportedly contributed to suppressing disease activity in a mouse model of rheumatoid arthritis (RA), suggesting new treatment options using Brazilian propolis. However, only results from animal experiments have been available, and the suppr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yoshinari Matsumoto, Kanae Takahashi, Yuko Sugioka, Kentaro Inui, Tadashi Okano, Koji Mandai, Yutaro Yamada, Ayumi Shintani, Tatsuya Koike
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/75560eafb16d41f599d07d6c6a569c2e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:75560eafb16d41f599d07d6c6a569c2e
record_format dspace
spelling oai:doaj.org-article:75560eafb16d41f599d07d6c6a569c2e2021-11-25T06:23:39ZDouble-blinded randomized controlled trial to reveal the effects of Brazilian propolis intake on rheumatoid arthritis disease activity index; BeeDAI.1932-620310.1371/journal.pone.0252357https://doaj.org/article/75560eafb16d41f599d07d6c6a569c2e2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252357https://doaj.org/toc/1932-6203<h4>Background and aims</h4>Brazilian propolis reportedly contributed to suppressing disease activity in a mouse model of rheumatoid arthritis (RA), suggesting new treatment options using Brazilian propolis. However, only results from animal experiments have been available, and the suppressive effects of Brazilian propolis on disease activity in humans with RA remain unknown. The purpose of this study was to clinically validate how Brazilian propolis intake changes disease activity in RA patients.<h4>Methods</h4>This study was conducted as a multicenter, double-blinded, randomized, placebo-controlled, parallel-group study of 80 women with RA (median age, 61.5 years; interquartile range, 56.0 to 67.3 years) showing moderate disease activity on Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR). Test tablets containing Brazilian propolis were used in Group P (40 patients), and Brazilian propolis-free placebo tablets were used as control in Group C (40 patients). Group P received 5 tablets of propolis (508.5 mg of propolis) daily, and Group C received 5 tablets of placebo daily. The intervention lasted 24 weeks, with change in DAS28-ESR set as the primary endpoint. As secondary endpoints, other disease activity assessment (DAS28 using C-reactive protein, simplified disease activity index, clinical disease activity index), ultrasonographic evaluation of synovitis, activities of daily living, quality of life, changes in cytokine levels, and adverse events over the course of the study were also assessed. Data were statistically analyzed by analysis of covariance.<h4>Results</h4>No significant differences in the primary endpoint were identified between groups (Group P vs Group C, effect: 0.14, 95% confidence interval: -0.21 to 0.49, p = 0.427). Likewise, no significant differences were seen between groups for any secondary endpoints. The adverse event rate during the study period was 28% in Group P and 33% in Group C.<h4>Conclusions</h4>Brazilian propolis exerted no effects on disease activity in patients with RA.Yoshinari MatsumotoKanae TakahashiYuko SugiokaKentaro InuiTadashi OkanoKoji MandaiYutaro YamadaAyumi ShintaniTatsuya KoikePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 5, p e0252357 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Yoshinari Matsumoto
Kanae Takahashi
Yuko Sugioka
Kentaro Inui
Tadashi Okano
Koji Mandai
Yutaro Yamada
Ayumi Shintani
Tatsuya Koike
Double-blinded randomized controlled trial to reveal the effects of Brazilian propolis intake on rheumatoid arthritis disease activity index; BeeDAI.
description <h4>Background and aims</h4>Brazilian propolis reportedly contributed to suppressing disease activity in a mouse model of rheumatoid arthritis (RA), suggesting new treatment options using Brazilian propolis. However, only results from animal experiments have been available, and the suppressive effects of Brazilian propolis on disease activity in humans with RA remain unknown. The purpose of this study was to clinically validate how Brazilian propolis intake changes disease activity in RA patients.<h4>Methods</h4>This study was conducted as a multicenter, double-blinded, randomized, placebo-controlled, parallel-group study of 80 women with RA (median age, 61.5 years; interquartile range, 56.0 to 67.3 years) showing moderate disease activity on Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR). Test tablets containing Brazilian propolis were used in Group P (40 patients), and Brazilian propolis-free placebo tablets were used as control in Group C (40 patients). Group P received 5 tablets of propolis (508.5 mg of propolis) daily, and Group C received 5 tablets of placebo daily. The intervention lasted 24 weeks, with change in DAS28-ESR set as the primary endpoint. As secondary endpoints, other disease activity assessment (DAS28 using C-reactive protein, simplified disease activity index, clinical disease activity index), ultrasonographic evaluation of synovitis, activities of daily living, quality of life, changes in cytokine levels, and adverse events over the course of the study were also assessed. Data were statistically analyzed by analysis of covariance.<h4>Results</h4>No significant differences in the primary endpoint were identified between groups (Group P vs Group C, effect: 0.14, 95% confidence interval: -0.21 to 0.49, p = 0.427). Likewise, no significant differences were seen between groups for any secondary endpoints. The adverse event rate during the study period was 28% in Group P and 33% in Group C.<h4>Conclusions</h4>Brazilian propolis exerted no effects on disease activity in patients with RA.
format article
author Yoshinari Matsumoto
Kanae Takahashi
Yuko Sugioka
Kentaro Inui
Tadashi Okano
Koji Mandai
Yutaro Yamada
Ayumi Shintani
Tatsuya Koike
author_facet Yoshinari Matsumoto
Kanae Takahashi
Yuko Sugioka
Kentaro Inui
Tadashi Okano
Koji Mandai
Yutaro Yamada
Ayumi Shintani
Tatsuya Koike
author_sort Yoshinari Matsumoto
title Double-blinded randomized controlled trial to reveal the effects of Brazilian propolis intake on rheumatoid arthritis disease activity index; BeeDAI.
title_short Double-blinded randomized controlled trial to reveal the effects of Brazilian propolis intake on rheumatoid arthritis disease activity index; BeeDAI.
title_full Double-blinded randomized controlled trial to reveal the effects of Brazilian propolis intake on rheumatoid arthritis disease activity index; BeeDAI.
title_fullStr Double-blinded randomized controlled trial to reveal the effects of Brazilian propolis intake on rheumatoid arthritis disease activity index; BeeDAI.
title_full_unstemmed Double-blinded randomized controlled trial to reveal the effects of Brazilian propolis intake on rheumatoid arthritis disease activity index; BeeDAI.
title_sort double-blinded randomized controlled trial to reveal the effects of brazilian propolis intake on rheumatoid arthritis disease activity index; beedai.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/75560eafb16d41f599d07d6c6a569c2e
work_keys_str_mv AT yoshinarimatsumoto doubleblindedrandomizedcontrolledtrialtorevealtheeffectsofbrazilianpropolisintakeonrheumatoidarthritisdiseaseactivityindexbeedai
AT kanaetakahashi doubleblindedrandomizedcontrolledtrialtorevealtheeffectsofbrazilianpropolisintakeonrheumatoidarthritisdiseaseactivityindexbeedai
AT yukosugioka doubleblindedrandomizedcontrolledtrialtorevealtheeffectsofbrazilianpropolisintakeonrheumatoidarthritisdiseaseactivityindexbeedai
AT kentaroinui doubleblindedrandomizedcontrolledtrialtorevealtheeffectsofbrazilianpropolisintakeonrheumatoidarthritisdiseaseactivityindexbeedai
AT tadashiokano doubleblindedrandomizedcontrolledtrialtorevealtheeffectsofbrazilianpropolisintakeonrheumatoidarthritisdiseaseactivityindexbeedai
AT kojimandai doubleblindedrandomizedcontrolledtrialtorevealtheeffectsofbrazilianpropolisintakeonrheumatoidarthritisdiseaseactivityindexbeedai
AT yutaroyamada doubleblindedrandomizedcontrolledtrialtorevealtheeffectsofbrazilianpropolisintakeonrheumatoidarthritisdiseaseactivityindexbeedai
AT ayumishintani doubleblindedrandomizedcontrolledtrialtorevealtheeffectsofbrazilianpropolisintakeonrheumatoidarthritisdiseaseactivityindexbeedai
AT tatsuyakoike doubleblindedrandomizedcontrolledtrialtorevealtheeffectsofbrazilianpropolisintakeonrheumatoidarthritisdiseaseactivityindexbeedai
_version_ 1718413751015702528